Search company, investor...
PlenOptika company logo


Founded Year



Incubator/Accelerator - II | Alive

Total Raised


About PlenOptika

PlenOptika is enabling eye care for all with the QuckSee--a device that prescribes eyeglasses at the push of a button. It is based on wavefront aberrometry and measures the full aberration fingerprint of the eye, enabling an accurate prescription to be calculated. It is smaller than a laptop, rugged, and battery-powered.

Headquarters Location

Harvard Innovation Launch Lab 114 Western Avenue

Boston, Massachusetts, 02134,

United States


Missing: PlenOptika's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: PlenOptika's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing PlenOptika

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

PlenOptika is included in 3 Expert Collections, including Medical Devices.


Medical Devices

8,592 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items


Clinical Encounter Tech

625 items

PlenOptika Patents

PlenOptika has filed 2 patents.

The 3 most popular patent topics include:

  • Ophthalmic equipment
  • Ophthalmology
  • Optometry
patents chart

Application Date

Grant Date


Related Topics




Ophthalmology, Sensors, Optometry, Vision, Geometrical optics


Application Date


Grant Date



Related Topics

Ophthalmology, Sensors, Optometry, Vision, Geometrical optics



Latest PlenOptika News

QuickSee handheld autorefractor can dramatically increase access to eyeglasses, study finds

Jun 21, 2021

Device designed to reduce global uncorrected refractive error News provided by Share this article Share this article CAMBRIDGE, Mass., June 21, 2021 /PRNewswire/ -- A new paper published by researchers at the Aravind Eye Institute in India, Johns Hopkins University, and the Massachusetts Eye and Ear Institute found that eyeglasses made from QuickSee handheld autorefractor measurements were accepted equally to those made from subjective refraction measurements. The study authors suggest that QuickSee, due to its accuracy and portability, could be used to radically expand access to eyeglasses in remote and low resource settings which lack professionals and clinical equipment to provide accurate prescriptions. PlenOptika's QuickSee handheld autorefractor in use in India. The paper in Ophthalmology, " Investigation of the accuracy of a low-cost, portable, autorefractor to provide well-tolerated eyeglass prescriptions: a randomized crossover trial ," concluded that patients accepted eyeglasses made from QuickSee measurements equally to those made from subjective refraction. PlenOptika, the maker of QuickSee, assisted in study design but its execution, analysis, and reporting were independent of the company. Uncorrected refractive error is a matter of major global concern, including wealthy nations. A report published by The Lancet in February 2021, " The Lancet Global Health Commission on Global Eye Health: vision beyond 2020 ," estimated that over 1 billion people worldwide had distance- or near-vision impairment, resulting in at least $410 billion in productivity loss annually. The authors also highlighted the impact of poor vision on quality of life, education, and workforce opportunities, noting that vision correction would support a number of the UN's Sustainable Development Goals . This is the challenge PlenOptika set out to solve. "These encouraging findings support our belief that the global burden of vision impairment can be met with innovative technology, not only in low- and middle-income countries, but also in wealthy countries like the US where vision care disparities persist," said Shivang Dave, PhD, CEO of PlenOptika and one of QuickSee's inventors. He and his colleagues in PlenOptika, Daryl Lim, PhD, Eduardo Lage, PhD, and Nicholas Durr, PhD, invented the technology while researchers at the Massachusetts Institute of Technology, in collaboration with the Regional Government of Madrid. QuickSee development was supported in part by grants from the National Eye Institute of the National Institutes of Health. In wealthy nations where patients have access to licensed health care providers, QuickSee's technology has also helped eye doctors provide on-site care, such as in nursing homes, correctional facilities, and community health centers. Even large eye health centers are using QuickSee to manage large patient volumes efficiently. Lage, PlenOptika's Chief Technology Officer, noted that impact in global health was QuickSee's central design objective. "Portable, durable, easy to use, and affordable, all without sacrificing clinical quality, that was our mission," he said. "It is gratifying that independent research affirms QuickSee's capability to achieve this." To date, QuickSee has been used to measure over three million people in 45 countries, and was found in prior peer-reviewed studies to produce measurements that strongly agree with subjective refraction. "Our goal with QuickSee is nothing short of making accurate autorefraction accessible to everyone, everywhere, enhancing their opportunities and enabling the wonder of clear vision," said Dave. "We hope this research gives vision care professionals, healthcare organizations, and NGOs the confidence that QuickSee will be instrumental in their work to dramatically increase access to vision correction." About PlenOptika PlenOptika designs and produces tools to help vision professionals perform their best care anywhere. Inspired to solve the global burden of poor vision, we developed QuickSee™, the world's most accurate handheld autorefractor. Vision professionals and NGOs have used QuickSee on over 3 million patients in 45 countries to transform their lives with clear vision. Contact

PlenOptika Frequently Asked Questions (FAQ)

  • When was PlenOptika founded?

    PlenOptika was founded in 2014.

  • Where is PlenOptika's headquarters?

    PlenOptika's headquarters is located at Harvard Innovation Launch Lab, Boston.

  • What is PlenOptika's latest funding round?

    PlenOptika's latest funding round is Incubator/Accelerator - II.

  • How much did PlenOptika raise?

    PlenOptika raised a total of $50K.

  • Who are the investors of PlenOptika?

    Investors of PlenOptika include ScaleUp, Harvard Venture Incubation Program, Massachusetts Institute of Technology and Nina Capital.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.